Focus: Italfarmaco Research is a specialty pharmaceutical company based in Italy focused on neurology, primarily leveraging a single blockbuster asset (Riluzole) for amyotrophic lateral sclerosis treatment.
Profile data last refreshed 2h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Italfarmaco Research to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Anchor product now in post-LOE decline; generic ANDA competition eroding branded position.
Help build intelligence for Italfarmaco Research
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Italfarmaco Research's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
NDA-approved liquid formulation offering improved patient convenience; minor revenue contributor despite peak lifecycle status.
Additional ANDA generic riluzole; further commoditization of core asset.
Additional ANDA generic riluzole; further commoditization of core asset.
Additional ANDA generic riluzole; further commoditization of core asset.
Additional ANDA generic riluzole; further commoditization of core asset.
Original NDA formulation with approaching LOE; flagship branded product facing patent cliff pressure.
HDAC inhibitor NDA with growth trajectory and extended patent protection to 2040; represents only meaningful pipeline diversification.
Enteral suspension NDA formulation; LOE approaching 2029 alongside broader riluzole franchise erosion.
Additional ANDA generic riluzole; further commoditization of core asset.
5 discontinued, 4 duplicate formulations not shown
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moActive product shortage in flagship asset combined with zero hiring and minimal pipeline suggests operational and strategic distress; elevated reputational and employment stability risk.